CRDF vs. BEAT
CRDF (Cardiff Oncology, Inc.) and BEAT (Heartbeam, Inc.) are both stocks. Over the past 3 years, CRDF returned -22.67%/yr vs -45.19%/yr for BEAT. Their 0.14 correlation means their historical movements had little consistent relationship.
Performance
CRDF vs. BEAT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRDF achieves a -69.56% return, which is significantly higher than BEAT's -79.14% return.
CRDF
- 1D
- 0.52%
- 1M
- -32.65%
- 6M
- -51.12%
- YTD
- -69.56%
- 1Y
- -67.60%
- 3Y*
- -22.67%
- 5Y*
- -30.62%
- 10Y*
- -45.93%
- ALL TIME*
- -29.15%
BEAT
- 1D
- -3.21%
- 1M
- -30.47%
- 6M
- -65.48%
- YTD
- -79.14%
- 1Y
- -50.92%
- 3Y*
- -45.19%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -39.60%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
BEAT Heartbeam, Inc. | $175.70K | $598.50K | $582.72K |
| $927.22K | $1.64M | $2.02M |
CRDF vs. BEAT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CRDF Cardiff Oncology, Inc. | -69.56% | -35.25% | 193.24% | 5.71% | -76.71% | 6.75% |
BEAT Heartbeam, Inc. | -79.14% | 4.35% | -2.13% | -51.84% | 58.44% | -42.96% |
Correlation
The correlation between CRDF and BEAT is 0.20, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.20 |
Correlation (3Y) Balances recent behavior with more history. | 0.15 |
Correlation (All Time) Calculated using the full available price history since Nov 11, 2021 | 0.14 |
Fundamentals
CRDF:
$56.14M
BEAT:
$17.24M
CRDF:
-$0.66
BEAT:
-$0.56
CRDF:
1.68
BEAT:
32.00
CRDF:
$484.00K
BEAT:
$0.00
CRDF:
-$11.32M
BEAT:
$0.00
CRDF:
-$45.29M
BEAT:
-$20.29M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRDF vs. BEAT — Risk / Return Rank
CRDF
BEAT
CRDF vs. BEAT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cardiff Oncology, Inc. (CRDF) and Heartbeam, Inc. (BEAT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRDF | BEAT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.40 | ||
| Sortino ratioReturn per unit of downside risk | -1.24 | ||
| Omega ratioGain probability vs. loss probability | 0.86 | 1.04 | -0.18 |
| Calmar ratioReturn relative to maximum drawdown | -0.86 | -0.65 | -0.20 |
| Martin ratioReturn relative to average drawdown | -1.63 | -1.03 | -0.60 |
Loading charts...
Drawdowns
CRDF vs. BEAT - Drawdown Comparison
The maximum CRDF drawdown since its inception was -99.96%, which is greater than BEAT's maximum drawdown of -91.57%. Use the drawdown chart below to compare losses from any high point for CRDF and BEAT.
Loading charts...
Drawdown Indicators
| CRDF | BEAT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.96% | -91.57% | -8.39% |
Max Drawdown (1Y)Largest decline over 1 year | -74.77% | -85.45% | +10.68% |
Max Drawdown (3Y)Largest decline over 3 years | -86.29% | -85.45% | -0.84% |
Max Drawdown (5Y)Largest decline over 5 years | -89.31% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -99.82% | — | — |
Current DrawdownCurrent decline from peak | -99.96% | -91.57% | -8.39% |
Average DrawdownAverage peak-to-trough decline | -86.29% | -63.51% | -22.78% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.16% | 54.22% | -15.06% |
Volatility
CRDF vs. BEAT - Volatility Comparison
Cardiff Oncology, Inc. (CRDF) has a higher volatility of 41.18% compared to Heartbeam, Inc. (BEAT) at 26.30%. This indicates that CRDF's price experiences larger fluctuations and is considered to be riskier than BEAT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRDF | BEAT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 41.18% | 26.30% | +14.88% |
Volatility (6M)Calculated over the trailing 6-month period | 65.40% | 63.45% | +1.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 83.91% | 152.81% | -68.90% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 101.00% | 117.06% | -16.06% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 106.16% | 117.06% | -10.90% |
Dividends
CRDF vs. BEAT - Dividend Comparison
Neither CRDF nor BEAT has paid dividends to shareholders.
Financials
CRDF vs. BEAT - Financials Comparison
This section allows you to compare key financial metrics between Cardiff Oncology, Inc. and Heartbeam, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CRDF and BEAT have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRDF has higher volatility (41.18%) compared to BEAT (26.30%). In terms of maximum drawdown, CRDF dropped -99.96% vs BEAT's -91.57%.
BEAT currently has the higher Sharpe Ratio (-0.37 vs -0.76), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRDF and BEAT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer